Uterine Fibroids: Pathophysiology and Novel Therapies Exploring the Molecular Mechanisms Behind Fibroid Development and the Effectiveness of Emerging Non-Surgical Treatment Options

Abstract

Uterine fibroids (UFs), also known as leiomyomas, are the most common benign tumors affecting women of reproductive age. Despite their benign nature, fibroids often lead to significant morbidity, including excessive menstrual bleeding, pelvic pain, and infertility. Recent advances in our understanding of the molecular mechanisms underlying fibroid development have paved the way for novel non-surgical therapies. This study aims to explore the pathophysiology of uterine fibroids in detail and analyze the effectiveness of emerging treatment modalities, including hormonal agents, selective progesterone receptor modulators (SPRMs), GnRH antagonists, and minimally invasive procedures like high-intensity focused ultrasound (HIFU) and radiofrequency ablation (RFA). Our results highlight significant improvements in fibroid size reduction, symptom alleviation, and patient quality of life through these novel approaches. Statistical analysis of treatment outcomes across multiple studies is presented in the form of tables, bar charts, and pie charts, offering clear insights into the most effective treatment options available today.